Comorbidity in chronic obstructive pulmonary disease

Respiratory Investigation

Volumn 53, Issue 6, 2015, Pages 249-258

  Negewo, Netsanet A ^a   McDonald, Vanessa M ^a,b   Gibson, Peter G ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Comorbidities; COPD; Disease management; Disease prevalence

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANEMIA; ANXIETY DISORDER; ASTHMA; BRONCHIECTASIS; CARDIOVASCULAR DISEASE; CATARACT; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LENGTH OF STAY; MENTAL DISEASE; METABOLIC DISORDER; MYOPATHY; OBESITY; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SLEEP DISORDERED BREATHING; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; GASTROINTESTINAL DISEASES; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION DISORDERS;

CARDIOVASCULAR DISEASES; COGNITION DISORDERS; COMORBIDITY; GASTROINTESTINAL DISEASES; HUMANS; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASES; OSTEOPOROSIS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION DISORDERS;

EID: 84945441272     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2015.02.004     Document Type: Review

References (106)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. Available from: ; 2014 [last accessed 16.04.14]. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf.
2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013, 380:2095-2128.
4. Gibson GJ, Loddenkemper R, Lundback B, et al. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J 2013, 42:559-563.
5. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD?-Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003, 97:115-122.
6. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011, 139:752-763.
7. Kurmi OP, Semple S, Simkhada P, et al. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax 2010, 65:221-228.
8. Po JY, Fitz Gerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax 2011, 66:232-239.
9. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009, 374:733-743.
10. Stoller JK AL. Alpha1-antitrypsin deficiency. Lancet 2005, 365:2225-2236.
11. WHO. Causes of COPD. Available from: [last accessed 29.11.14]. http://www.who.int/respiratory/copd/causes/en.
12. Tai A, Tran H, Roberts M, et al. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014, 69:805-810.
13. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
14. Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration 2012, 84:89-97.
15. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007, 370:797-799.
16. Agusti A, Soriano JB. COPD as a systemic disease. COPD 2008, 5:133-138.
17. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
18. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD 2008, 5:235-256.
19. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012, 12:26.
20. Lopez Varela MV, Montes de Oca M, Halbert R, et al. Comorbidities and health status in individuals with and without COPD in five Latin American cities: the PLATINO study. Arch Bronconeumol 2013, 49:468-474.
21. Corsonello A, Antonelli Incalzi R, Pistelli R, et al. Comorbidities of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2011, 17(Suppl. 1):S21-S28.
22. Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013, 107:1376-1384.
23. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013, 1:73-83.
24. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:728-735.
25. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
26. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, et al. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chronic Obstr Pulmon Dis 2012, 7:679-686.
27. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122.
28. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005, 26:1887-1894.
29. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005, 127:1531-1536.
30. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161.
31. Garcia-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract 2013, 14:11.
32. Tsiligianni IG, Kosmas E, van der Molen T, et al. Managing comorbidity in COPD: a difficult task. Curr Drug Targets 2013, 14(2):158-176.
33. Chhabra SK, Gupta M. Coexistent chronic obstructive pulmonary disease-heart failure: mechanisms, diagnostic and therapeutic dilemmas. Indian J Chest Dis Allied Sci 2010, 52:225-238.
34. Curkendall SM, deLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70.
35. Wang Y, Stavem K, Dahl FA, et al. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int J Chronic Obstr Pulmon Dis 2014, 9:99-105.
36. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009, 136:376-380.
37. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD 2010, 7:375-382.
38. Patel ARC, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011, 5(5):647-662.
39. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007, 30:616-622.
40. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
41. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001, 285:2486-2497.
42. Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005, 25:226-232.
43. Diez-Manglano J, Barquero-Romero J, Almagro P, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med 2013.
44. Vozoris NT, O'Donnell DE. Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease. Can Respir J 2012, 19:e18-e24.
45. McDonald VM, Simpson JL, Higgins I, et al. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2011, 40:42-49.
46. Cecere LM, Littman AJ, Slatore CG, et al. Obesity and COPD: associated symptoms, health-related quality of life, and medication use. COPD 2011, 8:275-284.
47. Vandenbergh E, Van de Woestijne KP, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis 1967, 95:556-566.
48. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1791-1797.
49. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
50. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:322-323.
51. Zapatero A, Barba R, Ruiz J, et al. Malnutrition and obesity: influence in mortality and readmissions in chronic obstructive pulmonary disease patients. J Hum Nutr Diet 2013, 26(Suppl. 1):S16-S22.
52. Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009, 34:209-218.
53. Lehouck A, Boonen S, Decramer M, et al. COPD, bone metabolism, and osteoporosis. Chest 2011, 139:648-657.
54. Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev 2013, 22:454-475.
55. Graat-Verboom L, van den Borne BE, Smeenk FW, et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 2011, 26:561-568.
56. Graat-Verboom L, Spruit MA, van den Borne BE, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: an underestimated systemic component. Respir Med 2009, 103:1143-1151.
57. Kim HC, Mofarrahi M, Hussain SN. Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int J Chronic Obstr Pulmon Dis 2008, 3:637-658.
58. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res 2001, 2:216-224.
59. Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014, 189:e15-e62.
60. Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014, 44:341-350.
61. McDonald VM, Higgins I, Gibson PG. Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges. Drugs Aging 2013, 30:1-17.
62. Abramson MJ, Perret JL, Dharmage SC, et al. Distinguishing adult-onset asthma from COPD: a review and a new approach. Int J Chronic Obst Pulmon Dis 2014, 9:945-962.
63. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 2009, 64:728-735.
64. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003, 124:474-481.
65. Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:823-831.
66. Carratu P, Resta O. Is obstructive sleep apnoea a comorbidity of COPD and is it involved in chronic systemic inflammatory syndrome?. Eur Respir J 2008, 31:1381-1382.
67. Agusti A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2012, 9:43-46.
68. Vijayan VK. Chronic obstructive pulmonary disease. Indian J Med Res 2013, 137:251-269.
69. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006, 100:115-122.
70. Zeki AA, Schivo M, Chan A, et al. The Asthma-COPD Overlap Syndrome: a common clinical problem in the elderly. J Allergy (Cairo) 2011, 2011:861926.
71. Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med 2014.
72. Menezes AM, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014, 145:297-304.
73. Hiestand D, Phillips B. The overlap syndrome: chronic obstructive pulmonary disease and obstructive sleep apnea. Crit Care Clin 2008, 24:551-563. vii.
74. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010, 182:325-331.
75. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011, 5:647-662.
76. Martinez CH, Okajima Y, Murray S, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respir Res 2014, 15:62.
77. Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Poorly treated or unrecognized GERD reduces quality of life in patients with COPD. Dig Dis Sci 2011, 56:1976-1980.
78. Mokhlesi B, Morris AL, Huang CF, et al. Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest 2001, 119:1043-1048.
79. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
80. Timms CJ, Yates DH, Thomas PS. Diagnosing GORD in respiratory medicine. Front Pharmacol 2011, 2:40.
81. An L, Lin YX, Yang T, et al. Predictive validity of BODE index for anxious and depressive symptoms in patients with chronic obstructive pulmonary disease. Chin Med J (Engl) 2010, 123:1845-1851.
82. Hill K, Geist R, Goldstein RS, et al. Anxiety and depression in end-stage COPD. Eur Respir J 2008, 31:667-677.
83. Zhang MW, Ho RC, Cheung MW, et al. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry 2011, 33:217-223.
84. Cafarella PA, Effing TW, Usmani ZA, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology 2012, 17:627-638.
85. McDonald CF, Khor Y. Advances in chronic obstructive pulmonary disease. Intern Med J 2013, 43:854-862.
86. Miyazaki M, Nakamura H, Chubachi S, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res 2014, 15:13.
87. Laurin C, Moullec G, Bacon SL, et al. Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med 2012, 185:918-923.
88. Abrams TE, Vaughan-Sarrazin M, Van der Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics 2011, 52:441-449.
89. Sonetti DA, Hospenthal AC, Adams SG. Integrated management strategies for chronic obstructive pulmonary disease. J Multidiscip Healthcare 2010, 3:181-188.
90. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005, 127:1205-1211.
91. Cleutjens FA, Janssen DJ, Ponds RW, et al. COgnitive-Pulmonary disease. Biomed Res Int 2014, 2014:697825.
92. Dodd JW, Charlton RA, van den Broek MD, et al. Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest 2013, 144:119-127.
93. Tulek B, Atalay NB, Yildirim G, et al. Cognitive function in chronic obstructive pulmonary disease: relationship to global initiative for chronic obstructive lung disease 2011 categories. Respirology 2014, 19:873-880.
94. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J 2010, 35:913-922.
95. Cleutjens FA, Wouters EF, Dijkstra JB, et al. The COgnitive-Pulmonary Disease (COgnitive-PD) study: protocol of a longitudinal observational comparative study on neuropsychological functioning of patients with COPD. BMJ Open 2014, 4:e004495.
96. Yohannes AM, Ershler WB. Anemia in COPD: a systematic review of the prevalence, quality of life, and mortality. Respir Care 2011, 56:644-652.
97. Krishnan G, Grant BJ, Muti PC, et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med 2006, 6:23.
98. Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007, 29:923-929.
99. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009, 122:348-355.
100. Weatherall M, Clay J, James K, et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 2009, 14:983-990.
101. Miller DP, Watkins SE, Sampson T, et al. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chronic Obst Pulmon Dis 2011, 6:467-476.
102. Roberts ER, Green D, Kadam UT. Chronic condition comorbidity and multidrug therapy in general practice populations: a cross-sectional linkage study. BMJ Open 2014, 4:e005429.
103. Fabbri LM, Luppi F, Beghe B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008, 31:204-212.
104. Muth C, Kirchner H, van den Akker M, et al. Current guidelines poorly address multimorbidity: pilot of the interaction matrix method. J Clin Epidemiol 2014, 67:1242-1250.
105. Fabbri LM, Boyd C, Boschetto P, et al. How to integrate multiple comorbidities in guideline development: article 10 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc 2012, 9:274-281.
106. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010, 376:803-813.